|Videos|June 2, 2022
Reflections on Novel Targets and Emerging Regimens for RCC
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5